RESUMEN
The middle Eocene Adelholzen beds were deposited on the northern part of the Tethyan shelf of the European Plate. In the Eastern Alps, the Wimmern section near Teisendorf (Germany) is the only known outcrop exposing the basal unconformity of this sequence. The outcrop comprises an 8 m thick condensed transgressive shallow marine succession characterized by glauconite-rich weakly consolidated greensand and mudstone containing abundant larger benthic foraminifera. It spans the lower part of calcareous nannoplankton Zone NP15 (Sub-Zones NP15a and lower part of NP15b), planktonic foraminifera Sub-Zone E7b and Zone E8 partim and the upper part of shallow benthic Zone SBZ13. The landward migration of the paleo-shoreline was not an effect of flexural downbending of the European Plate but can be correlated to the major unconformity at the base of eustatic supercycle TA3. The onset of this sea-level rise was in the latest part of Biochron NP14b and almost coincided with the NP14b/NP15a-boundary.
RESUMEN
Hepatitis C virus (HCV) infection invariably recurs after liver transplantation (LT), and sequels of chronic hepatitis of the graft are a significant cause of morbidity and mortality. In an uncontrolled trial, 31 patients with histologically confirmed hepatitis C after LT received, sequentially, ribavirin (10 mg/kg body weight q.d.) for 12 weeks, followed by ribavirin at the same dose q.d. plus interferon-alpha (IFN-alpha) [3 million units three times a week (3 MU TIW)] for another 48 weeks. Based on an intent-to-treat analysis, the percentages of patients with undetectable HCV RNA in their serum were 0%, 38.7% and 45.2% after 12, 36 and 60 weeks of therapy, respectively. A sustained virological response, as defined by undetectable serum HCV RNA 24 weeks after the end of treatment, was observed in 9/31 patients (29%). Sustained responders had a significant improvement of their liver inflammatory activity score (P=0.025), but not of their liver fibrosis score. The chances of sustained virological response correlated with the length of treatment, but not with the HCV genotype or baseline HCV RNA level. In conclusion, patients with recurrent hepatitis C after LT might benefit from ribavirin/IFN-alpha therapy, provided that the treatment is tolerated for a sufficient duration of time.
